Lyell Immunopharma (LYEL) announced the appointment of David Shook as CMO and Mark Meltz as general counsel and corporate secretary. Prior to Lyell, Shook was CMO and head of research and development at Nkarta (NKTX) where he was responsible for leading the clinical development of multiple CAR NK cell product candidates for oncology. Prior to joining Lyell, Meltz was COO and general counsel of Kinnate Biopharma.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL: